Neurodevelopmental Disorders | Employing iPSC Technologies to Define and Treat Childhood Brain Diseases
Langue : anglais
Edité par Springer International Publishing, 2021
- Livre broché
- Neuf
Vendeur : preigu, Osnabrück, Allemagnepreigu
Vendeur AbeBooks depuis 5 août 2024
Etat: Neuf
EUR 140,10
Quantité disponible : 5 disponible(s)
Ajouter au panierItem description from seller
N° de réf. du vendeur 120145828
- Titre
- Neurodevelopmental Disorders | Employing iPSC Technologies to Define and Treat Childhood Brain Diseases
- Auteur
- James H. Millonig (u. a.)
- Éditeur
- Springer International Publishing
- Année de publication
- 2021
- État de l'article
- Neu
- Reliure
- Taschenbuch
- Langue
- anglais
- ISBN à 10 chiffres
- 3030454959
- ISBN à 13 chiffres
- 9783030454951
- Poids de l'article
- 482 grammes
- Dimensions
- 235 x 155 x 18 mm
- Série
- Livre 1 sur 39: Advances in Neurobiology
- Catalogues du vendeur
- Bücher
This book contains a compendium of induced pluripotent stem cells (iPSCs) articles and reviews concerning state of the art technologies and how they are being applied to human neurodevelopmental disorders. With the establishment of effective technologies to produce iPSCs and their derivatives, like neural precursors, neurons, and glia, researchers have new platforms to study neurodevelopmental disorders. iPSC technology enables researchers to study how human neurons develop in individuals with neurodevelopmental disorders, providing an unparalleled opportunity to investigate their etiology. In turn, researchers have now begun to understand the underlying molecular and cellular pathways that contribute to human diseases. iPSCs technologies also provide an emerging tool for future translational studies and disease classification. The chapters will emphasize how among the diverse idiopathic and genetic disorders, there are common clinical as well as cellular andmolecular phenotypes.
« Synopsis » peut appartenir à une autre édition de cet ouvrage.
À propos de l’auteur
Dr. DiCicco-Bloom has broad experience performing basic and translational research on neurodevelopmental disorders including animal models and human induced pluripotent stem cells (iPCSs). As an active child neurologist, his research focuses on defining molecular and cellular pathways that regulate production of neuronal cells (neurogenesis) during brain development, and how related abnormalities contribute to developmental disorders including autism. He investigates how growth signals, genetic factors, and environmental toxins impact cell proliferation, survival, and fate determination during brain development using rat and mouse neural stem cells in culture and in vivo, with a focus on the cerebral cortex, cerebellum, and hippocampus. To begin defining mechanisms that are more directly relevant to human disorders, recent collaborative studies with Co-Editor James H. Millonig, Ph.D. have focused on creating human induced neural stem cells (NPCs) from people with autism, to determine their neurobiological signatures. Significantly, by comparing NPCs from two forms of autism, including idiopathic and genetically defined (CNV 16p11.2 Deletion Syndrome), these studies reveal a common neurobiological phenotype consisting of reduced neural process outgrowth and cell migration in autism compared to control NPCs. Moreover dysregulation of the mTOR signaling pathway appears to be central to these phenotypes, as pathway manipulation both corrects autism deficits and recreates abnormalities in relevant controls. This new era of exploring neuropsychiatric conditions in human neurons may provide more relevant cellular and molecular pathways on which to target therapeutic interventions that may be "personalized" to the needs of the specific individual.
Dr. DiCicco-Bloom has long served the autism scientific and advocacy communities, providing scientific expertise to federal agencies including NIH, DOD, NSF, and IACC, and disease advocacy organizations including National Alliance for Autism Research, Autism Science Foundation, Autism Speaks, Autism Tissue Program, Brain Canada, Rett Syndrome Foundation, and Simons Foundation. He Chaired the Scientific Program Committee of the 2008 International Meeting for Autism Research (IMFAR) meeting (London) and Co-Chaired 2010 (Philadelphia), and has long served the IMFAR Program Committee. For the Society for Neuroscience, he has served on many committees (PECC, GPA, Audit, Rigor and Reproducibility Working Group) and as a Councilor. Currently, he is Chair of the NIH Developmental Brain Disorders Study Section, is a member of the DOD Autism Research Program and the American Brain Coalition (ABC) Board of Directors, and serves as Scientific Advisor to the Eagles Autism Foundation. He serves on the editorial boards of Autism Research, Molecular Autism, and other developmental neuroscience journals, and has authored numerous research articles and book chapters in neuroscience, child neurology, and psychiatry.
James H. Millonig Ph.D. is associate professor in the department of Neuroscience and Cell Biology and resident member in the Center for Advanced Biotechnology and Medicine at Robert Wood Johnson Medical School-Rutgers University.
Dr. Millonig graduated from The University of Rochester magna cum laude with a B.S. in Biochemistry. After college he received a M.Sc. degree from Oxford University, University College studying B subtilis sporulation. Dr. Millonig matriculated in the Princeton University Molecular Biology PhD program and performed his thesis research in the lab of Shirley Tilghman Ph.D., President emerita of Princeton University. During his PhD, he was trained in genetics, mouse development, and molecular biology. Subsequent post-doctoral research, using mouse genetic approaches to study cerebellar development, was performed in Mary E. Hatten's laboratory at The Rockefeller University. He joined the faculty at Rutgers in 1999.
Dr. Millonig has studied CNS development throughout his career applying molecular genetic approaches to understand basic mechanisms and disease. His work in collaboration with Emanuel DiCicco-Bloom M.D. and Linda Brzustowicz M.D. demonstrated genetic association of ENGRAILED2 (EN2) with autism spectrum disorder and defined autism-like behaviors in mouse models thatcould be reversed by pharmacological treatment. His lab also identified the orphan GPCR, Gpr161, as an unknown, important regulator of neural tube closure and lens development. Forward mouse genetic approaches demonstrated that Gpr161 functions through the retinoic acid (RA) pathway. His lab is currently studying rare human mutations in the RA metabolic pathway and Gpr161 and their impact on development. More recently, Dr. Millonig and Dr. DiCicco-Bloom have applied iPSC-based approaches to study idiopathic and 16p11.2 Deletion Syndrome. They have defined neurodevelopmental phenotypes in culture and are applying numerous omic strategies to define the downstream signaling and cell biological pathways affected in autism. He is the recipient of many research awards including Basil O'Connor Starter Research Award, NARSAD Young Investigator Award, and the Thomas A Edison Patent Award for medical diagnostics. He has over 100 abstracts, papers, and grants related to autism and neurodevelopmental disorders. He has been an active reviewer for many scientific journals including Molecular Psychiatry, Translational Psychiatry, and eLife. For the NIH, he has been an ad hoc member of Clinical Neuroplasticity and Neurotransmitters and Genetics of Health and Disease, was a standing member of the NIH Developmental Brain Disorders Study Section (2010-16) and has also contributed to NIH Loan Repayment Program, BRAIN, and NIH Director's Early Independence Awards initiatives.
He is currently the Director of the Rutgers-RWJMS-Princeton University MD/PhD program and is senior associate dean in the Rutgers School of Graduate Studies. He was co-PI on an NIH Director's Fund Broadening Experiences Scientific Training (BEST) training grant. In these roles, Dr. Millonig has developed numerous educational initiatives including the BEST program called iJOBS, which includes all Rutgers campuses across NJ that has reached 836 trainees or 16,258 person hours in 4 years.
« A propos de ce titre » peut appartenir à une autre édition de cet ouvrage.
preigu
Osnabrück, Allemagne
Vendeur AbeBooks depuis 5 août 2024
Frais d'expédition de Allemagne vers Etats-Unis
| Article | 60 à 60 jours ouvrés | 60 à 60 jours ouvrés |
|---|---|---|
| Premier article | EUR 70,00 | EUR 70,00 |
Modes de paiement
Description de la boutique
Spécialité
Bücher, SpielwarenProfil professionnel du vendeur
preigu GmbH & Co. KG
Lengericher Landstraße 19
Osnabrück, Allemagne 49078
Conditions de vente
About Us
Legal website operator identification:
preigu GmbH & Co. KG
Lengericher Landstr. 19
49078 Osnabrück
Germany
Telephone: +49 (0) 541 / 580 72 84
Email: mail@preigu.de
VAT No: DE 455 380 498
AG Osnabrück - HRA 209647
PhG: preigu Verwaltung GmbH
AG Osnabrück - HRB 221793
CEO: Ansas Meyer
We are neither willing nor obliged to participate in dispute resolution proceedings before consumer arbitration boards.
We are a member of the initiative "FairCommerce" since 30.11.2016.
For more information, see: https://www.haendlerbund.de/de/haendlerbund/interessenvertretung/faircommerce
Droit de rétractation
Instructions for revocation
Right of withdrawal for the sale of goods
Revocation right for consumers
(A ‘consumer' is any natural person who concludes a legal transaction which, to an overwhelming extent, cannot be attributed to either his commercial or independent professional activities.)
Instructions for revocation
Revocation right
You have the right to revoke this contract within 14 days without specifying any reasons.
The revocation period is 14 days with effect from the day,
-
on which you or a third party nominated by you, which is not the carrier, had taken possession of the products, provided you had ordered one or more products within the scope of a standard order and this/these product/products is/are delivered uniformly;
-
on which you or a third party nominated by you, which is not the carrier, had taken possession of the last product, provided you had ordered several products within the scope of a standard order and these products are delivered separately;
-
on which you or a third party nominated by you, which is not the carrier, had taken possession of the last part delivery or the last unit, provided you had ordered a product, which is delivered in several part deliveries or units;
To exercise your right of withdrawal, you must inform us (preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, Telephone number: +49 (0) 541 / 580 72 84, E-Mail address: mail@preigu.de) by means of a clear declaration (e.g. a letter sent by post, or an e-mail) of your decision to withdraw from this contract. You can use the attached model withdrawal form for this purpose, which is, however, not mandatory.
You can also exercise your right of withdrawal online by clicking on a button labelled accordingly (such as ‘Withdraw from contract' or similar) on the AbeBooks/ZVAB website. If you use this online function, you will immediately receive a confirmation of receipt on a durable medium (e.g. via email) containing information on the content of the withdrawal notice, as well as the date and time of its receipt.
In order to safeguard the revocation period, it is sufficient that you send the notification about the exercise of the revocation right before the expiry of the revocation period.
Consequences of the revocation
If you revoke this contract, we shall repay all the payments, which we received from you, including the delivery costs (with the exception of additional costs, which arise from that fact that you selected a form of delivery other than the most reasonable standard delivery offered by us), immediately and at the latest within 14 days from the day on which we received the notification about the revocation of this contract from you. We use the same means of payment, which you had originally used during the original transaction, for this repayment unless expressly agreed otherwise with you; you will not be charged any fees owing to this repayment.
We can refuse the repayment until the products are returned to us or until you have furnished evidence that you have sent the products back to us, depending on whichever is earlier.
You must return or transfer the products to us immediately and, in any case, at the latest within 14 days with effect from the day on which you inform us of the revocation of this contract. The deadline is maintained if you send the products before the expiry of the 14 day deadline.
You bear the direct costs for returning the products.
You must pay for any depreciation of the products only if this depreciation can be attributed to any handling with you that was not necessary for checking the condition, features and functionality of the products.
Criteria for exclusion or expiry
The revocation right is not available for contracts
-
for delivery of products, which are not prefabricated and for whose manufacturing an individual selection or stipulation by the consumer is important or which are clearly tailored to the personal requirements of the consumer;
-
for delivery of products, which can spoil quickly or whose use-by date would be exceeded quickly;
-
for delivery of alcoholic drinks, whose price was agreed at the time of concluding the contract, which however can be delivered 30 days after the conclusion of the contract at the earliest and whose current value depends on the fluctuations in the market, on which the entrepreneur has no influence;
-
for delivery of newspapers, periodicals or magazines with the exception of subscription contracts. The revocation right expires prematurely in case of contracts
-
for delivery of sealed products, which are not suitable for return for reasons of health protection or hygiene if their seal has been removed after the delivery;
-
for delivery of products if they have been mixed inseparably with other goods after the delivery, owing to their condition;
-
for delivery of sound or video recording or computer software in a sealed package if the seal has been removed after the delivery.
Specimen - revocation form
(If you wish to revoke the contract, please fill up this form and send it back to us.)
-
To preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, Email address: mail@preigu.de :
-
I/we () herewith revoke the contract concluded by me/ us () regarding the purchase of the following products ()/
the provision of the following service () -
Ordered on ()/ received on ()
-
Name of the consumer(s)
-
Address of the consumer(s)
-
Signature of the consumer(s) (only in case of a notification on paper)
-
Date
(*) Cross out the incorrect option.